Gleevec

GPTKB entity

Statements (55)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:approves gptkb:2001
gptkb:FDA
gptkbp:available_on generic version
gptkbp:brand gptkb:imatinib_mesylate
gptkbp:chemical_formula C22 H26 N6 O2 S
gptkbp:clinical_trial Phase II
Phase III
Phase I
gptkbp:clinical_use targeted therapy
gptkbp:contraindication severe liver disease
hypersensitivity to imatinib
gptkbp:developed_by gptkb:Novartis
gptkbp:discovery gptkb:Dr._Nicholas_Lydon
gptkbp:discovery_year gptkb:1996
gptkbp:dosage_form oral tablet
gptkbp:effective_date gptkb:2001
gptkbp:fdaapproval_status approved
gptkbp:fdaapproval_type New Drug Application
https://www.w3.org/2000/01/rdf-schema#label Gleevec
gptkbp:indication gptkb:Philadelphia_chromosome-positive_leukemia
gptkb:dermatofibrosarcoma_protuberans
gptkb:myelodysplastic_syndromes
gptkbp:ingredients gptkb:imatinib
gptkbp:interacts_with gptkb:warfarin
certain antibiotics
certain antifungals
certain anticonvulsants
gptkbp:invention gptkb:Novartis_AG
gptkb:2015
gptkbp:marketed_as gptkb:Europe
gptkb:Gleevec
gptkb:Canada
gptkb:United_States
gptkbp:mechanism_of_action tyrosine kinase inhibitor
gptkbp:name Essential Medicines List
gptkbp:previous_name gptkb:imatinib
gptkbp:research_areas molecular biology
oncology
hematology
pharmacology
gptkbp:route_of_administration oral
gptkbp:safety Category D
gptkbp:shelf_life 3 years
gptkbp:side_effect fatigue
nausea
diarrhea
edema
gptkbp:storage room temperature
gptkbp:trade gptkb:Gleevec
gptkbp:used_for gptkb:chronic_myeloid_leukemia
gptkb:gastrointestinal_stromal_tumors
gptkbp:weight 493.6 g/mol
gptkbp:bfsParent gptkb:Novartis
gptkbp:bfsLayer 4